How the ryan Seacrest Health Department designed its ‘toxic’ new drug
- by admin
The ryan-designed drug, named TMAO, has been found to be safe and well tolerated for people with diabetes, hypertension, heart disease, and other serious diseases.
The FDA’s decision to approve TMAP was based on a safety study and the fact that the drug is approved for other conditions with similar side effects, according to a letter sent by Seacstest’s senior vice president, Stephen M. P. Haggerty, to the FDA.
“The safety of the drug has been established, and we will continue to work with the FDA to develop new options for treating patients with these conditions,” the letter said.TMAO is the first drug in the world to use the same drug to treat two separate conditions: type 1 diabetes and type 2 diabetes.
It is also the first medication to target both types of diabetes simultaneously.
TMA is currently being evaluated by FDA, the American Diabetes Association and other health care organizations.
In the letter, Haggercyt said the drug’s FDA approval was based upon “a scientific study conducted by the FDA and other entities” that were independent of Seacsts.
“It is the FDA’s determination that the safety of TMAo is established and is based on all of the available data, including the available scientific data that we have collected,” the FDA wrote in its letter to the Seacstrest team.
Haggerty said the agency is still evaluating the drug and is looking for additional data to determine whether the drug poses a higher risk of causing adverse side effects than other insulin-lowering drugs.
The FDA said in its response that it would not be releasing additional information about the safety study until it was done.
Hagancyt also sent a letter to Seacsters co-founder and chief executive officer, Scott A. Hall, and his team in the FDA last month asking for the agency to review the drug.
“As part of our ongoing efforts to address the concerns that have arisen with the drug, and as part of the broader regulatory review process, we are working with the Department of Health and Human Services, the Food and Drug Administration, and the Federal Trade Commission to expedite the review of the FDA review of TAAO,” Hagancyti wrote.
Hall did not respond to a request for comment.
“I am hopeful that we will be able to move quickly through the FDA regulatory process to protect our consumers and provide more certainty for the thousands of Americans who are taking TAAOs,” Hall said in a statement.
The company is in the midst of developing its own insulin-replacement therapy, called TAAOT.
Haganphyt said in the letter that the FDA will work with Hall to expeditiously get TAAOP approved.
Hagans letter to Hagancys letter said the company plans to make its next drug available to the market within the next three months.
The ryan-designed drug, named TMAO, has been found to be safe and well tolerated for people with diabetes, hypertension, heart…